3-oxo-octanal | 3223-40-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-oxo-octanal
• 英文别名: 3-Oxooctanal
• CAS: 3223-40-3
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: RBSGNVCVLXKKFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-oxo-octanal 在 palladium on activated charcoal 硫酸 、 氢气 、 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 1,3,5-三正己基苯
  参考文献：
  名称：

  Synthesis of 1,3,5-tri-n-alkylbenzene compounds

  摘要：

  DOI：

  10.1021/jo00258a037
• 作为产物：
  描述：

  2-庚酮 生成 3-oxo-octanal
  参考文献：
  名称：

  Bokadia; Deshapande, Journal of the Indian Chemical Society, 1953, vol. 30, p. 383,385

  摘要：

  DOI：

文献信息

• [EN] TRICYCLIC HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011059784A1

  公开（公告）日：2011-05-19

  Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物或其立体异构体或盐，其中：X1、X2、X3、W、Q1、Q2和G2在此处被定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，如自身免疫疾病和血管疾病。
• [EN] AMIDES AS PIM INHIBITORS<br/>[FR] AMIDES CONVENANT COMME INHIBITEURS DES PIM
  申请人：AMGEN INC

  公开号：WO2013130660A1

  公开（公告）日：2013-09-06

  The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  本发明涉及式(1)的含酰胺化合物及其盐。在一些实施例中，本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含本文披露的化合物的药物组合物，及其用于预防治疗Pim激酶相关状况和疾病，尤其是癌症的应用。
• [EN] 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,3-DIAZA-SPIRO-[3.4]-OCTANE
  申请人：GRUENENTHAL GMBH

  公开号：WO2019012037A1

  公开（公告）日：2019-01-17

  The invention relates to 1,3-diaza-spiro-[3.4]-octane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.

  这项发明涉及1,3-二氮杂螺[3.4]-辛烷衍生物，它们的制备和在医学中的应用，特别是在各种神经系统疾病中，包括但不限于疼痛、神经退行性疾病、神经炎症性疾病、神经精神疾病、物质滥用/依赖。
• [EN] EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS<br/>[FR] COMPOSÉS ÉPIDITHIODICÉTOPIPÉRAZINES, COMPOSITIONS ET PROCÉDÉS
  申请人：GLOBAVIR BIOSCIENCES INC

  公开号：WO2015095821A1

  公开（公告）日：2015-06-25

  Epidithiodiketopiperazine compounds, pharmaceutical compositions based thereon and methods of their synthesis, as part of treating, inhibiting and reducing transcription and translation of hypoxia inducible genes are described. In another aspect, the present disclosure describes a method for interfering with hypoxia-induced transcriptional pathway in a cell comprising: contacting the cell with at least one compound disclosed herein. In another aspect, the present disclosure describes a method for treating breast cancer, a solid cancer, a blood cancer, a subject suffering from carcinoma in need of said treatment, and renal cell carcinoma (RCC), comprising: administering to the subject an effective amount of at least one compound disclosed herein. In some embodiments of the methods described herein, the method further comprises administering an additional anti-cancer and/or cytotoxic agent.

  描述了Epidithiodiketopiperazine化合物、基于该化合物的药物组合物及其合成方法，作为治疗、抑制和减少低氧诱导基因的转录和翻译的一部分。在另一个方面，本公开说明描述了一种干扰细胞中低氧诱导转录途径的方法，包括：将细胞与至少一种本公开披露的化合物接触。在另一个方面，本公开说明描述了一种治疗乳腺癌、实体癌、血液癌、需要接受所述治疗的患有癌症的受试者以及肾细胞癌（RCC）的方法，包括：向受试者施用至少一种本公开披露的化合物的有效量。在所述方法的一些实施方式中，该方法还包括施用额外的抗癌和/或细胞毒药剂。
• METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING
  申请人：Seed Brian

  公开号：US20100055761A1

  公开（公告）日：2010-03-04

  The present invention provides methods and compositions for treating various diseases through selective killipg of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.

  本发明提供了一种通过组合靶向方法选择性杀死靶向细胞治疗各种疾病的方法和组合物。本发明特征在于原毒素融合蛋白质包含一个细胞靶向部分和一个可修改的激活部分，该激活部分通过不在目标细胞上、内、周围自然可操作发现的激活部分被激活。这些方法还包括组合使用两种或更多治疗剂，至少包括原毒素和原毒素激活剂，以靶向和摧毁特定细胞群体。